TABLE 1.
Frequencies of resistance-conferring mutations in RT of RT-SHIV-infected animals before and after treatment as determined by ASP
| Animal | Treatment group | Wk postinfection | Wk post-initiation of treatment
|
Frequency of mutation (%)c
|
|||||
|---|---|---|---|---|---|---|---|---|---|
| K65R | K103N
|
M184I | M184V | ||||||
| EFV | ART | AAC | AAT | ||||||
| M03250 | EFV monotherapy | 13 | 0 | 0 | — | — | — | — | — |
| 14 | 1 | 0 | — | 8 | 13 | ||||
| 17 | 4 | 0 | — | 12 | 18 | — | — | ||
| 23 | NAd | 6 | 18 | 24 | 1 | 3 | — | ||
| 24 | NA | 7 | 5 | 60 | 0.3 | 24 | 0.5 | ||
| 25 | NA | 8 | 3 | 94 | 0.07 | 71 | 7 | ||
| 26 | NA | 9 | 1 | 100 | — | 88 | 6 | ||
| M04007 | EFV monotherapy | 13 | 0 | 0 | NDe | ND | ND | ND | ND |
| 17 | 1 | 0 | — | — | — | — | — | ||
| 40 | NA | 23a | — | — | — | — | — | ||
| 49 | NA | 32b | — | — | — | — | — | ||
| M04008 | EFV monotherapy | 13 | 0 | 0 | — | — | — | — | — |
| 15 | 1 | 0 | — | 18 | 21 | — | — | ||
| 17 | NA | 0 | — | 8 | 16 | — | — | ||
| 21 | NA | 4 | — | 15 | 10 | — | — | ||
| 25 | NA | 8 | — | 20 | 15 | — | — | ||
| 28 | NA | 11 | — | 14 | 21 | — | — | ||
| 40 | NA | 23a | — | 5 | 31 | — | — | ||
| 47 | NA | 30b | — | 27 | 40 | — | — | ||
| K02396 | No monotherapy | 13 | NA | 0 | ND | ND | ND | ND | ND |
| 17 | NA | 0 | — | — | — | — | — | ||
| 39 | NA | 22a | — | — | — | — | — | ||
| 47 | NA | 30b | — | — | — | — | — | ||
| M03430 | No monotherapy | 13 | NA | 0 | ND | ND | ND | ND | ND |
| 17 | NA | 0 | — | — | — | — | — | ||
| 47 | NA | 30b | — | — | — | — | — | ||
| M04033 | No monotherapy | 13 | NA | 0 | ND | ND | ND | ND | ND |
| 17 | NA | 0 | — | — | — | — | — | ||
| 40 | NA | 23a | — | — | — | — | — | ||
| 47 | NA | 30b | — | — | — | — | — | ||
a
During treatment interruption.
b
After discontinuation of ART.
c
—, none detected; limit of detection, 0.01% for K103N AAC or K103N AAT, 0.3% for M184V, 0.05% for M184I, and 0.2% for K65R.
d
NA, not applicable.
e
ND, not done.